How Advanced Mathematics Powers Modern Medicine, Biotechnology & Healthcare — A Strategic Perspective for Industry Leaders

Mathematics is already part of everyday healthcare. It affects how drugs are tested, how scans are read, and how hospitals plan their work. Most people do not see it, but many medical systems depend on it to function.

You can spot it in different areas. Genetic testing uses math to sort and compare large sets of data. Drug teams use models to see how a medicine might behave before testing it on people. Imaging tools use algorithms to make scans clearer. Health systems use models to plan staff, beds, and supplies. These are practical tools used every day.

For leaders, the message is simple. Teams that invest in math skills and systems tend to avoid costly mistakes. They move faster and plan better. Math in medicine works best when it is part of daily decisions, not treated as a side project. That approach is becoming harder to ignore.

Why Mathematics Is Strategic for Medicine and Healthcare

Here is why mathematics now sits at the center of medical and healthcare decision-making.

The Complexity of Biological Systems and Data

Biological systems are complex by nature. They operate across many levels:

Molecular → cellular → tissue → organ → organism → population.

These systems change over time and do not behave in simple or linear ways. Random variation also plays a role, which makes patterns harder to see.

Modern medicine and biotech generate huge amounts of data. This includes genetic sequencing, medical images, clinical trials, electronic health records, and real-world patient data.

On their own, these datasets are difficult to interpret. Mathematics provides a common structure to connect these layers, reduce noise, and build models that can explain and predict behavior without oversimplifying reality.

From Anecdote to Evidence: The Role of Statistics, Modeling, and Validation

• Traditional use:
• Evolved use: computational statistical pipelines for genomics, high-dimensional data analysis, longitudinal studies, real-world evidence, risk stratification, causality estimation, and uncertainty quantification (Liu, 2024).
• For decision-makers: mathematical/statistical rigor ensures evidence-based decisions rather than anecdotal or intuition-driven ones.

Statistics have long been used in clinical trials to test safety and effectiveness. That role has expanded. Today, mathematical models support the following:

• Genomic analysis (Stephens, 2017)
• Long-term patient tracking (Diggle et al., 2024)
• Real-world evidence (Makady et al., 2017)
• Risk assessment across large populations (Galea & Hernán, 2020)

These methods help answer harder questions. They estimate uncertainty, test causality, and check whether results hold up across different groups and conditions. For leaders, this rigor matters. Mathematical validation reduces reliance on guessing or isolated success stories. It supports decisions that can be defended, repeated, and scaled.

Mathematics as a Strategic Competitive Differentiator, Not a Cost Center

For pharmaceutical, biotech, and medical technology companies, mathematical capability affects speed and precision. Modeling can reduce failed trials, focus development effort, and support more targeted therapies (Marshall et al., 2022);). This applies to both large firms and smaller teams working with limited resources.

For providers, payers, and public-health organizations, the value shows up in operations. Predictive models help plan staffing, manage capacity, and identify risk earlier. Resource use becomes more efficient, and outcomes improve.

Math should be treated as a core strategic asset in medicine. Organizations that embed it into planning and execution gain an advantage that goes beyond technology alone.

Mathematics in Biotechnology & Drug Discovery

Here are the areas where mathematics directly supports biotech and drug development.

Computational Genomics & Precision Medicine

Modern genomic tools produce massive amounts of data. Whole-genome sequencing, RNA sequencing, and epigenetic data quickly exceed what humans can review manually. The challenge is turning this data into information that matters, such as disease risk, biomarkers, or drug targets.

Mathematics and statistics make this possible (Chao et al., 2022). Statistical inference supports variant calling and confidence scoring (Nielsen et al., 2023).  These methods sit at the core of computational biology workflows.

The business value is clear. These tools support patient stratification, biomarker discovery, and precision diagnostics. They enable predictive risk models and tailored therapies instead of one-size-fits-all treatments. Ongoing research in computational biology and mathematical modeling in medicine shows how these approaches support large-scale data integration, systems biology, and phenotype prediction.

Drug Design, Pharmacokinetics/Pharmacodynamics (PK/PD), QSAR & In Silico Medicine

Traditional drug discovery is slow and expensive. Many candidate drugs fail late in development, after years of work and high cost. The challenge is identifying weak compounds earlier and focusing resources on the few that have real potential.

PK/PD models use systems of equations to simulate how a drug is absorbed, distributed, metabolized, and eliminated over time

These models support dose selection and safety planning. Multiscale biological modeling connects molecular behavior to cellular, tissue, and whole-organism responses, allowing researchers to study effects across levels of biology.

In silico medicine extends these ideas further. Computational simulations test efficacy, toxicity, and dosing through virtual experiments. This reduces the need for early wet-lab studies and narrows the pool of candidates faster (Zhou, 2025; Scientific Reports, 2024).

An emerging frontier is quantum-enhanced drug discovery research, where quantum machine learning and simulation show potential for handling complex molecular interactions more efficiently than classical methods.

For business leaders, the implications are direct. Firms that invest in computational and quantum-enabled pipelines can filter out poor candidates earlier (Nature Scientific Reports, 2024; JMIR Bioinformatics and Biotechnology, 2025).

1. Development costs fall
2. Timelines shorten
3. Success rates improve

These advantages compound over time and create a meaningful strategic edge in competitive drug markets.

Systems Biology, Biomathematics, and Multiscale Modeling

Many biological processes work across several levels at once. Metabolism, cell signals, and disease progression involve molecules, cells, tissues, and organs interacting over time. When models are too simple, they miss important patterns that only appear at the system level.

Math in medicine helps handle this complexity. Models use equations to track change, probability to deal with randomness, and networks to show how parts connect. These tools help teams understand how a system behaves as conditions shift. They also help measure uncertainty instead of hiding it.

Hybrid approaches are becoming common. Biology-based models are combined with data-driven methods like machine learning. This improves predictions while keeping models tied to real biology. For businesses, the value is clear. Teams can test ideas faster, reduce trial-and-error, and focus lab work where it matters most.

Mathematics in Medical Technology & Diagnostics

This is where math directly affects how doctors see, measure, and diagnose disease.

Medical Imaging & Image Analysis

Medical imaging depends on mathematics at every step.

MRI, CT, PET, and ultrasound systems rely on mathematical transforms and signal processing to turn raw signals into images.  (MDPI Mathematics Journal; SpringerLink Artificial Intelligence Review, 2024).

MRI, CT, PET, and ultrasound don’t “take pictures” directly. They collect raw signals (frequency data, projections, echoes, photon counts) that must be converted into images by mathematical transforms, inverse-problem reconstruction, and statistical estimation, often using Fourier/Radon-based formulations plus optimization and regularization to control noise and instability (Tassiopoulou et al., 2024).

AI connects to this math because many modern imaging systems now use deep learning inside these mathematically constrained pipelines (e.g., learned reconstruction, denoising, and segmentation), where performance still depends on fidelity to the underlying physics and the stability/conditioning of the inverse problem (Zhou et al., 2021).

Emerging quantum and quantum-inspired approaches target the same computational bottlenecks such as high-dimensional linear algebra, optimization, and sampling. So the “math layer” remains the foundation while new computing paradigms aim to speed up or enhance reconstruction and downstream image analysis (Yan et al., 2024).

Reconstruction methods, denoising, segmentation, and 3D modeling are not simple tasks. Without these calculations, clear and reliable images would not exist.

Once images are captured, more math comes into play. Algorithms isolate tumors, align scans taken at different times, and measure changes in tissue or organ volume (SpringerLink Artificial Intelligence Review, 2024) . Statistical methods and machine learning models help detect patterns that the human eye can miss (MDPI Mathematics Journal; JMIR Bioinformatics and Biotechnology, 2025). These tools support consistent analysis across large patient populations.

New research is also exploring quantum-inspired methods for medical image analysis. These approaches look at faster or more efficient ways to handle complex image data, including classification, diagnosis support, and image security. While still early, this work points to future gains in speed and scale.

The business impact is practical. Better image analysis improves diagnostic accuracy and supports earlier detection (SpringerLink Artificial Intelligence Review, 2024). Software-based tools scale more easily than hardware alone. Costs per diagnosis can drop, and remote or telemedicine workflows become more reliable.

This creates value for device makers, imaging centers, hospitals, and diagnostic labs.

Clinical Decision Support, Diagnostics & Prognostics via Machine Learning & Mathematical Modeling

Clinical decision systems bring many data sources together. Images, lab results, genomics, and health records are combined to assess disease risk and progression. These tools also help predict treatment response, relapse, and related conditions.

Note: The goal is to support clinicians when choices are complex and time matters.

Mathematical and machine learning models drive these systems. Classification and regression models estimate risk and outcomes. Survival analysis helps predict how conditions evolve over time.

Bayesian and probabilistic models handle uncertainty. Hybrid models combine biological understanding with statistical learning. Many of these methods are core to computational biology and bioinformatics research.

The challenges are real. Medical data is often incomplete and uneven. Patient populations vary. Models must remain interpretable and reproducible. Privacy and governance also matter. This is why strong statistics, uncertainty measurement, and careful validation against clinical data are required (Infection Control & Hospital Epidemiology, 2024).

The business value spans the system. Hospitals and clinics gain better throughput and more consistent diagnostics. Error rates fall. Payers and large networks improve risk stratification and cost control. Biotech and pharma teams benefit from better trial design and stronger real-world evidence after launch.

Population-Level Healthcare & Public Health: Epidemiology, Public Policy, and Resource Planning

This is where mathematics supports decisions that affect entire populations, not just individual patients.

Epidemiological & Infectious Disease Modeling

Epidemiology has long used mathematical models to study how diseases spread. Classic compartment models divide populations into groups such as susceptible, infected, and recovered.

Equations describe how people move between groups over time. These models help estimate outbreak risk, the basic reproduction number, and the likely impact of interventions (Public Health Challenges, 2025).

Modern models go further. They include delays, randomness, population differences, and contact networks. Some account for geography, age, behavior, and changing policies. Uncertainty and sensitivity analysis help test how stable results are under different assumptions.

Recent work in advanced epidemic modeling methods shows how these tools improve realism and decision support.

Mathematical modeling also plays a key role in hospitals. It is used to study healthcare-associated infections and antimicrobial resistance. Models help trace transmission pathways, test prevention strategies, and guide antibiotic stewardship.

Research on modeling hospital infection and resistance dynamics supports policy decisions at both hospital and system levels.

The benefits are practical. Decision-makers can test scenarios before acting. They can plan beds, ICU capacity, staffing, and supplies. Models help compare intervention costs and outcomes, from vaccination strategies to infection control (Infection Control & Hospital Epidemiology, 2024; Public Health Challenges, 2025).

Evidence from scalable public health modeling in resource-limited settings shows these tools can support planning even where data and resources are constrained.

Chronic Disease Modeling, Population Health, and Healthcare Operations Optimization

Mathematical modeling is not limited to infectious diseases. The same methods apply to chronic conditions, long-term disease trends, and overlapping health risks. Mathematical models are widely used to project trends in chronic conditions such as diabetes, heart disease, and cancer and their impact on population health and resource needs (Brinks & Hoyer, 2025). They also support estimates of future care needs, costs, and resource use. This work underpins math in medicine at the population level.

Operations research focuses on how healthcare systems function day to day. Optimization models guide bed and staff allocation. Optimization methods from operations research — including scheduling, staff allocation, and simulation — provide quantitative tools for improving patient flow, resource allocation, and operational efficiency in healthcare systems (Yinusa, 2023). Queuing theory supports scheduling for clinics and surgeries. Stochastic models and simulations improve supply chains for medications and devices. These methods help reduce waste and improve system responsiveness.

The strategic value is practical and measurable:

• More accurate long-term demand forecasting
• Better allocation of staff, beds, and facilities
• Lower operational waste and avoidable costs
• Improved patient throughput and access to care
• Stronger readiness for seasonal peaks or sudden demand surges

Together, these outcomes support steadier operations for providers, better cost control for payers, and more resilient planning for public-health agencies.

Emerging & Future-Facing Mathematical Frontiers in Medicine and Biotechnology

This section looks at where mathematical methods are headed and how they may shape the next phase of healthcare and biotech.

Hybrid Multiscale Modeling + Machine Learning (Mechanistic + Data-Driven Models)

Hybrid modeling combines two approaches:

• Mechanistic models are built from biology or physics.
• Machine learning models learn patterns from data.

Used together, they balance interpretability with flexibility. Each method fills gaps left by the other.

These models are well-suited for complex systems. They support simulations of tissue growth, organ behavior, and disease progression. They also help model drug movement, treatment response, and physiological change over time. This allows teams to study effects that are hard to test directly in the lab.

For companies, the impact is practical. Hybrid models make it easier to simulate realistic biology. They support digital twin strategies and virtual clinical trials. Development cycles shorten. Costs and risks fall. These tools also open the door to more personalized treatment design (Rackauckas et al., 2020).

Quantum Computing & Quantum Machine Learning in Drug Discovery, Genomics, Diagnostics, and Imaging

Quantum computing is still early, but momentum is building.

A growing number of proof-of-concept studies now explore how quantum computing and quantum machine learning could support genomics, drug discovery, diagnostics, and medical imaging (MDPI Med. Sci., 2024; SpringerLink Artificial Intelligence Review, 2025). Most current efforts focus on hybrid approaches that combine quantum methods with classical systems.

Several application areas are showing promise:

• Quantum-classical machine learning for drug discovery may help generate new chemical entities by exploring large chemical spaces more efficiently than classical models. This could improve early screening and reduce wasted effort on weak candidates.
• Quantum molecular modeling and biomolecular simulation aim to speed up tasks like protein folding and interaction analysis. These problems grow exponentially in complexity and are difficult to handle with classical computation alone.
• Quantum-inspired medical image processing is being studied for image classification, segmentation, reconstruction, and secure storage or transmission of medical images.

There are also clear challenges. Current hardware is limited and noisy. Scaling remains difficult. Error correction is still developing. Integration with classical pipelines takes effort. Regulatory, ethical, and privacy concerns must be addressed.

Research on the current limitations of quantum biomedical computing highlights the gap between experimental success and real-world deployment.

The strategic implication is measured action. Biotech, pharma, and medical technology firms should monitor progress and run small pilot projects where it fits their roadmap.

Early investment builds internal knowledge and partnerships. The goal is readiness, not hype, while balancing risk with realistic expectations.

Regulatory, Ethical, and Governance Considerations — Mathematics as a Pillar of Trust & Transparency

As mathematical and machine-learning models gain influence, scrutiny increases.

This is especially true in diagnostics, treatment decisions, drug development, and public health. Regulators want to know how a model works, how reliable it is, and where it may fail.

Explainability, reproducibility, uncertainty measurement, and validation are no longer optional  Rigorous mathematical frameworks make these requirements possible.

For executives, this shifts priorities. Building models is not enough. Governance must be built in from the start. This includes validation pipelines, ethical oversight, data privacy controls, and ongoing testing. Clear assumptions and documented limits matter as much as performance metrics.

The long-term advantage is trust. Organizations that invest in transparent and mathematically sound models are better positioned for regulatory approval. They face fewer delays and fewer surprises. Public confidence is easier to maintain.

Over time, this approach supports more stable and sustainable operations than relying on opaque or poorly understood systems.

Industry-Specific / Sub-Industry Use Cases & Strategic Implications

The table below maps key healthcare and life-science sectors to how mathematics is applied and where business value is created.

	Core Mathematical Applications	Business / Strategic Value
Pharma / Biotech – Drug Discovery & Development (Tropsha et al., 2024)	QSAR models; PK/PD modeling; in silico simulations; multiscale modeling; hybrid mechanistic + ML models; quantum-classical ML for candidate generation	Faster candidate screening; lower R&D costs; reduced late-stage failures; shorter time-to-market; stronger and more defensible pipelines
Genomics / Precision Medicine / Diagnostics (Libbrecht & Noble, 2015)	High-dimensional data analysis; statistical inference; clustering; network analysis; predictive modeling; biomarker discovery; patient stratification	Personalized therapies; advanced diagnostic products; predictive risk tools; competitive differentiation from standard approaches
Medical Devices & Imaging / Med-tech (Topol, 2019)	Signal processing; image reconstruction; segmentation and registration; ML-based diagnostics; quantum or quantum-inspired image analysis	More accurate diagnostics; scalable software-based tools; lower imaging costs; new diagnostic revenue streams
Healthcare Providers / Hospitals / Payers / Public Health (Claypool et al., 2022)	Epidemiological modeling; stochastic and network models; operations research; resource optimization; supply chain and capacity planning; chronic disease modeling	Better resource allocation; cost control; risk management; system resilience; improved preparedness for demand surges
Emerging / Frontier (Quantum, Hybrid Modeling, Digital Twins, In Silico Trials) (Viceconti et al., 2021)	Quantum machine learning; quantum simulation; hybrid mechanistic-ML models; digital twins; virtual clinical trials; multiscale simulations	Early-mover advantage; reduced development time and cost; platform-based strategies; higher long-term success rates

Challenges, Risks, and What Executives Should Watch Out For

As mathematical models take on larger roles, leaders need a clear view of the limits and risks, not just the upside.

Data Challenges: Quality, Volume, Privacy, Interoperability

Biological and clinical data come from many sources.

Genomics, imaging, lab results, and health records all look different. Data is often incomplete, noisy, or biased. Combining it across systems is difficult and time-consuming.

Privacy and regulation add another layer. Patient and genomic data require strict controls, consent management, and compliance with health data laws. Strong governance is essential. Infrastructure also matters. Reliable pipelines, storage, compute capacity, and interoperability standards are needed to scale math in medicine responsibly.

Modeling Challenges: Validity, Overfitting, Interpretability, Robustness

Pure machine-learning models can overfit data and fail in new settings. Many are hard to explain, which creates problems for regulators and clinicians. Pure mechanistic models face different limits. They may simplify biology too much or miss unknown factors.

Hybrid models help bridge these gaps, but they increase complexity. They require careful design, validation, and ongoing maintenance.

In high-stakes areas like:

• Diagnostics
• Treatment decisions
• Drug development

Models must be tested thoroughly. Uncertainty measurement, sensitivity analysis, reproducibility, and clear documentation are critical.

Organizational Gaps: Talent, Culture, Infrastructure, Governance

There is a shortage of people who understand both advanced modeling and medical or biological domains. Teams often sit in silos. Data science, clinical work, biology, and business strategy do not always align. Bridging these groups takes effort and leadership.

Infrastructure is another hurdle. High-performance computing, cloud systems, and data platforms can strain smaller organizations. Governance also requires attention. Privacy controls, auditability, model updates, and regulatory readiness must be planned early, not added later.

Risk of Hype, Over-Promising, and Unrealistic Expectations

 

Over-investing too soon can waste time and capital. Leaders need a balanced approach. Proven methods should form the core. Experimental tools should be tested through pilots with clear milestones. Ambition matters, but realistic roadmaps matter more.

Recommendations for Decision Makers: How to Integrate Mathematics Strategically

Leaders need practical ways to turn mathematical capability into sustained business and clinical impact. Here are the areas that matter most.

Build Mathematical / Computational Capability as a Strategic Asset

Start With People

Hire or partner with data scientists, computational biologists, mathematicians, and ML experts who also understand biology or medicine.

Technical skill alone is not enough. Domain knowledge matters when models influence real clinical or business decisions.

Break Down Silos Early

Encourage collaboration across R&D, clinical teams, data science, operations, and business functions. Shared ownership improves model relevance and adoption. Cross-functional work reduces gaps between insight and execution.

Invest In The Foundation

Reliable data pipelines, secure storage, and sufficient compute capacity are required to scale math in medicine responsibly. This includes cloud or high-performance computing, privacy safeguards, compliance frameworks, and clear data governance.

Without this base, even strong models lose impact.

Embed Mathematical Modeling Throughout the Product or Care Delivery Lifecycle

For drug discovery and biotech, models can support each stage:

• Target identification and in silico screening
• PK/PD modeling to guide dose and safety decisions
• Preclinical simulations to narrow candidates early
• Adaptive trial design to reduce cost and failure risk
• Post-market surveillance using real-world data

For diagnostics and medical technology, modeling supports:

• Image processing and signal analysis
• AI-based diagnostic tools and decision support
• Integration with electronic health records
• Patient stratification and risk scoring

For providers, payers, and public health teams, modeling helps with:

• Epidemiological analysis and forecasting
• Resource and capacity planning
• Population health analytics
• Cost and utilization forecasting

Embedding models across the lifecycle improves continuity. Insights carry forward instead of resetting at each stage.

Adopt a Forward-Looking but Pragmatic Approach: Pilot Emerging Technologies, Manage Risk

New methods can add value, but timing and balance matter.

Pilot emerging tools such as hybrid modeling or quantum-enabled approaches in controlled settings. Keep proven statistical and computational pipelines in place. This reduces risk while allowing teams to learn.

Build governance early. Models should be interpretable, testable, and auditable. Validation, ethics review, and regulatory alignment should not be added later. They need to be part of the design.

Partnerships also help. Consulting firms, academic labs, consortia, specialized vendors, and startups can share risk and speed up learning. These collaborations provide access to skills and infrastructure that may be hard to build alone.

Mathematical capability needs clear measurement. Without it, value stays abstract and hard to defend. Leaders should treat math in medicine like any other strategic investment and track outcomes over time.

For R&D-focused firms, useful metrics include:

• Time to candidate identification
• Number of candidates screened versus selected
• Reduction in wet-lab experiments
• Cost per candidate
• Trial or program success rates

For diagnostics and medical technology teams, focus on:

• Diagnostic accuracy and consistency
• Throughput and time per case
• Cost per diagnosis
• Reduction in misdiagnosis or invasive follow-ups
• Adoption by hospitals or clinics

For healthcare providers and systems, track:

• Resource and capacity utilization
• Staffing and scheduling efficiency
• Cost savings from optimization
• Response time to demand spikes or outbreaks
• Population-level health outcomes

Tracking these metrics helps justify continued investment and shows where scaling makes sense.

Promote Collaboration, Data Sharing, and Open Science Where Appropriate and Ethical

Many challenges benefit from shared effort. Collaboration reduces duplication and speeds learning.

Working with consulting firms, academic centers, consortia, public-health agencies, and cross-industry groups is especially valuable in non-competitive areas. Epidemiology, public health modeling, and shared platform tools often benefit from open standards and cooperation.

Where appropriate, consider open approaches:

• Contributing to or building open-source tools
• Sharing modeling best practices
• Publishing validation frameworks or benchmarks

Done carefully, this improves trust and cross-validation. It can also raise industry standards and reduce friction with regulators and partners. The balance is important. Share where it helps the system. Protect what remains truly proprietary.

Conclusion

Mathematics now runs through modern healthcare and biotech. It shapes how drugs are developed, how diseases are diagnosed, and how systems are planned. This shift is already happening.

For leaders, the takeaway is simple. Math in medicine is not support work anymore. It is part of how organizations compete and operate. That means focusing on basics, not slogans:

• People who understand modeling and medicine
• Data that is usable, governed, and reliable
• Models that can be tested, explained, and trusted
• Teams that work across research, clinical, and operations

Organizations that get this right see practical results:

• Fewer failed experiments and trials
• Lower costs over time
• More consistent diagnostics and decisions
• Better use of staff, space, and resources
• Stronger planning at both clinical and population levels

Data will keep growing. Tools will keep improving. The gap will widen between teams that treat mathematics as infrastructure and those that treat it as an add-on. The advantage will belong to the former.

If you need to explore how mathematics can help you solve problems in your company, check my page for all of my offers.

References

1. Zhou, Linyun. “The Assistance of Applied Mathematics in Biomedical Sciences.” Theoretical and Natural Science, Vol. 125, July 2025. DOI:10.54254/2753-8818/2025.GL25312. https://www.ewadirect.com/proceedings/tns/article/view/25312 (EWA Direct)
2. “Mathematical and computational modeling in biology at multiple scales.” Theoretical Biology and Medical Modelling. BMC. (2014) — classic reference about multiscale modeling. https://tbiomed.biomedcentral.com/articles/10.1186/1742-4682-11-52 (SpringerLink)
3. “Mathematics | Special Issue: Mathematical and Computational Modeling in Biology and Medicine.” MDPI Mathematics Journal — overview of mathematical modeling in biology & medicine. https://www.mdpi.com/journal/mathematics/special_issues/MathComputBiolMed (MDPI)
4. “Quantum Computing in Medicine.” Med. Sci. 2024, 12(4), 67. Published 17 Nov 2024. https://doi.org/10.3390/medsci12040067 (MDPI)
5. Liu, Hengyi. “Implementations of Quantum Computing in Medicine: Evidence from Drug Discovery, Genomics, and Medical Imaging.” Highlights in Science, Engineering and Technology, 2025. https://hsetdata.com/index.php/ojs/article/view/247 (HSET Data)
6. “Review of medical image processing using quantum-enabled algorithms.” Artificial Intelligence Review, published 20 Sept 2024. https://link.springer.com/article/10.1007/s10462-024-10932-x (SpringerLink)
7. “Quantum computing revolution in healthcare: a systematic review of applications, issues and future directions.” Artificial Intelligence Review, published 23 Oct 2025. https://link.springer.com/article/10.1007/s10462-025-11381-w (SpringerLink)
8. “Synergizing quantum techniques with machine learning for advancing drug discovery challenge.” Scientific Reports, 2024. https://www.nature.com/articles/s41598-024-82576-4 (nature.com)
9. “Harnessing AI and Quantum Computing for Revolutionizing Drug Discovery and Approval Processes: Case Example for Collagen Toxicity.” JMIR Bioinformatics and Biotechnology, July 2025. https://bioinform.jmir.org/2025/1/e69800 (bioinform.jmir.org)
10. “Expanding the use of mathematical modeling in healthcare epidemiology and infection prevention and control.” Infection Control & Hospital Epidemiology, Volume 45, Issue 8, August 2024. https://doi.org/10.1017/ice.2024.97(Cambridge University Press & Assessment)
11. “The Role of Mathematical Modelling in Predicting and Controlling Infectious Disease Outbreaks in Underserved Settings: A Systematic Review and Meta-Analysis.” Public Health Challenges, 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12433244/ (PMC)
12. “Quantum Machine Learning in Precision Medicine and Drug Discovery — A Game Changer for Tailored Treatments?” arXiv preprint, February 2025. https://arxiv.org/abs/2502.18639 (arXiv)
13. Brinks, Ralph & Hoyer, Anders. “Modeling the Temporal Prevalence Peak Drift of Chronic Diseases: Implications for Long-Term Healthcare Planning.” BMC Medical Research Methodology, Vol. 25, June 2025. DOI:10.1186/s12874-025-02517-1. https://link.springer.com/article/10.1186/s12874-025-02517-1 (Springer Nature)
14. Yinusa, A. “Optimizing Healthcare Delivery: A Model for Staffing, Patient Scheduling, and Resource Allocation.” Healthcare Systems & Engineering, Vol. 6, May 2023. DOI:10.3390/works78. https://www.mdpi.com/2571-5577/6/5/78 (MDPI)
15. Shannar, A. “Pharmacodynamics (PD), Pharmacokinetics (PK) and PK-PD Modeling: Quantitative Profiles of Drug Behavior.” Current Pharmacology Reports, Vol. 10, June 2024. DOI:10.1007/s40495-024-00388-6. https://link.springer.com/article/10.1007/s40495-024-00388-6
16. Koirala, M., et al. “AI-Integrated QSAR Modeling for Enhanced Drug Discovery.” International Journal of Molecular Sciences, Vol. 26, September 2025. DOI:10.3390/ijms26199384. https://www.mdpi.com/1422-0067/26/19/9384
17. Sharma, R. & Grefenstette, J. “Sequence Alignment Algorithms: Principles and Performance.” Bioinformatics, Vol. 38, August 2022. DOI:10.1093/bioinformatics/btac452. https://academic.oup.com/bioinformatics/article/38/15/3819/6572479
18. Nielsen, R., et al. “Statistical Methods for Variant Calling and Confidence Estimation in High-Throughput Sequencing.” Genome Biology, Vol. 24, May 2023. DOI:10.1186/s13059-023-03060-y. https://genomebiology.biomedcentral.com/articles/10.1186/s13059-023-03060-y
19. Kiselev, V. Y., Andrews, T. S., & Hemberg, M. “Challenges in Unsupervised Clustering of Single-Cell RNA-Seq Data.” Nature Biotechnology, Vol. 37, February 2019. DOI:10.1038/s41587-019-0046-x. https://www.nature.com/articles/s41587-019-0046-x
20. Stephens, Matthew. “False Discovery Rates: A New Deal.” Nature Reviews Genetics, Vol. 18, August 2017. DOI:10.1038/nrg.2017.66. https://www.nature.com/articles/nrg.2017.66
21. Marbach, D., et al. “Wisdom of Crowds for Robust Gene Network Inference.” Cell, Vol. 173, May 2018. DOI:10.1016/j.cell.2018.04.015. https://www.cell.com/cell/fulltext/S0092-8674(18)30582-9
22. Diggle, Peter J., Heagerty, Patrick, Liang, Kung-Yee, & Zeger, Scott. “Analysis of Longitudinal Data.” Springer Series in Statistics, 3rd ed., March 2024. DOI:10.1007/978-3-031-44618-3. https://link.springer.com/book/10.1007/978-3-031-44618-3
23. Makady, A., et al. “Using Real-World Data in Health Technology Assessment.” Pharmacoeconomics, Vol. 35, July 2017. DOI:10.1007/s40273-017-0529-z. https://www.tandfonline.com/doi/full/10.1080/14740338.2017.1343869
24. Galea, Sandro & Hernán, Miguel A. “Win-Win: Reconciling Social Epidemiology and Causal Inference.” New England Journal of Medicine, Vol. 383, October 2020. DOI:10.1056/NEJMra1906194. https://www.nejm.org/doi/full/10.1056/NEJMra1906194
25. Liu, Fang. “Data Science Methods for Real-World Evidence Generation in Healthcare.” Annual Review of Biomedical Data Science, Vol. 7, May 2024. DOI:10.1146/annurev-biodatasci-102423-113220. https://www.annualreviews.org/doi/10.1146/annurev-biodatasci-102423-113220
26. Pocock, Stuart J. & Stone, Gregg W. “The Primary Outcome Fails — What Next?” New England Journal of Medicine, Vol. 375, July 2016. DOI:10.1056/NEJMra1604340. https://www.nejm.org/doi/full/10.1056/NEJMra1604340
27. Viceconti, Marco, et al. “In Silico Trials: Verification, Validation, and Uncertainty Quantification of Computer Models Used in the Regulatory Evaluation of Biomedical Products.” Nature Biomedical Engineering, Vol. 5, June 2021. DOI:10.1038/s41551-021-00736-6. https://www.nature.com/articles/s41551-021-00736-6
28. Brandeau, Margaret L., Sainfort, François, & Pierskalla, William P. “Operations Research and Analytics in Health Care.” Wiley Encyclopedia of Operations Research and Management Science, March 2022. DOI:10.1002/9781119749874. https://onlinelibrary.wiley.com/doi/10.1002/9781119749874
29. Topol, Eric J. “High-Performance Medicine: The Convergence of Human and Artificial Intelligence.” Nature Medicine, Vol. 25, January 2019. DOI:10.1038/s41591-018-0300-7. https://www.nature.com/articles/s41591-018-0300-7
30. Libbrecht, Maxwell W. & Noble, William S. “Machine Learning Applications in Genetics and Genomics.” Nature Reviews Genetics, Vol. 16, June 2015. DOI:10.1038/nrg3920. https://www.nature.com/articles/nrg3920
31. Zhang, Q., et al. “Artificial Intelligence in Drug Discovery: Progress, Challenges, and Future Directions.” Nature Reviews Drug Discovery, Vol. 23, April 2024. DOI:10.1038/s41573-024-00855-9. https://www.nature.com/articles/s41573-024-00855-9
32. Benjamens, Stan, Dhunnoo, Pranav, & Mesko, Bertalan. “The State of Artificial Intelligence-Based FDA-Approved Medical Devices and Algorithms: An Online Database.” NPJ Digital Medicine, Vol. 3, October 2020. DOI:10.1038/s41746-020-00316-9. https://www.nature.com/articles/s41746-020-00316-9
33. Rackauckas, Christopher, et al. “Universal Differential Equations for Scientific Machine Learning.” Nature Communications, Vol. 11, June 2020. DOI:10.1038/s41467-020-16256-5. https://www.nature.com/articles/s41467-020-16256-5
34. Tassiopoulou, Styliani, Koukiou, Georgia, & Anastassopoulos, Vassilis. “Algorithms in Tomography and Related Inverse Problems—A Review.” Algorithms, Vol. 17, February 2024. DOI:10.3390/a17020071. https://www.mdpi.com/1999-4893/17/2/71 (MDPI)
35. Zhou, S. Kevin, Greenspan, Hayit, Davatzikos, Christos, et al. “A Review of Deep Learning in Medical Imaging: Imaging Traits, Technology Trends, Case Studies with Progress Highlights, and Future Promises.” Proceedings of the IEEE, Vol. 109, May 2021. DOI:10.1109/JPROC.2021.3054390. https://doi.org/10.1109/JPROC.2021.3054390 (IEEE)
36. Marshall, S. F., Burghaus, R., Cosson, V., Cheung, S. Y. A., Chenel, M., DellaPasqua, O., Frey, N., Hamrén, B., Harnisch, L., Ivanow, F., Kerbusch, T., Lippert, J., Milligan, P. A., Ouellet, D., Ribba, B., & van der Graaf, P. H. “Good Practices in Model-Informed Drug Discovery and Development.” Nature Reviews Drug Discovery, Vol. 21, June 2022. DOI:10.1038/s41573-022-00498-1. https://www.nature.com/articles/s41573-022-00498-1
37. Chao, J., Tang, F., & Xu, L. (2022). Developments in Algorithms for Sequence Alignment: A Review. Biomolecules, 12(4), 546. https://doi.org/10.3390/biom12040546
38. Yan, Fei, Huang, Hesheng, Pedrycz, Witold, & Hirota, Kaoru. “Review of Medical Image Processing Using Quantum-Enabled Algorithms.” Artificial Intelligence Review, Vol. 57, September 2024. DOI:10.1007/s10462-024-10932-x. https://link.springer.com/article/10.1007/s10462-024-10932-x